CVS Drops Obesity Drug; Once-Weekly Growth Hormone; WeightWatchers’ Bankruptcy

(MedPage Today) — Many patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor of semaglutide (Wegovy), despite the latter yielding less weight loss. (New York Times)
Transmasculine…